Neurodegeneration
Does Alzheimer’s tau hit retinal ganglion cells early?
Open access · cc by · source: Europe PMC
In 41 donor eyes, MCI and AD retinas showed pS396-tau and oligomeric tau inside RGCs, ~50% ganglion-cell loss, and correlations with brain AD stage and cognition.
Study at a glance
- Design
- Case-control — Human donor retina/brain comparison of AD dementia, MCI due to AD, and cognitively normal controls
- N
- N=41 · AD dementia n=15, MCI due to AD n=10, CN controls n=16
- Population
- Human retinal superior-temporal cross-sections and matched brain donors spanning MCI due to AD, AD dementia, and CN controls
- Outcome
- Pathogenic tau in RGCs (pS396-tau, oligomeric tau), RGC loss/morphology, and correlations with brain AD pathology and cognition
Structured fields used in claim comparison tables when every cited study has a complete layer.
Key findings
First evidence of RGCs laden with pS396-tau and oligomeric tau in MCI and AD, with hypertrophic somas and apoptotic/GVD-necroptotic markers, ~50% RGC loss, and strong correlations between tau-laden RGCs and brain AD pathology, stage, and cognition.
Methodology
Quantified RGC number, morphology, and abnormal tau isoforms (pS396-tau, Oligo-tau) in superior temporal retina from MCI due to AD, AD dementia, and CN controls, and related findings to brain pathology and cognitive status.
Limitations
Postmortem case-control data cannot prove retinal imaging will diagnose living patients; further work is needed before using tau-laden RGCs as a clinical biomarker.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
Tau tends to sit in network hubs and tracks weaker cortical connectivity in AD.
In Alzheimer’s disease, tau PET burden concentrated in highly connected cortical hubs and higher overall tau associated with weakened cortical connection strength; progressive-supranuclear-palsy patterns differed, showing disease-specific mapping of tau onto networks.
Scope note — postmortem retinal pS396/oligomeric tau in RGCs — not cortical tau PET connectome mapping
Limits the claim's scope: a different population, assay, or outcome.
A clinic plasma panel plus genetics can discriminate clinical AD from older controls without being autopsy-confirmed diagnosis.
In the AD Cardiff Cohort (1,439 clinical AD cases, 508 older controls), plasma Aβ40/42, P-tau181, NfL, and GFAP plus APOE-ε4 and polygenic risk reached AUC 0.81. Aβ-related peptides were lower in cases; P-tau181, NfL, and GFAP were higher. Case-only GWAS linked the Aβ42/Aβ40 ratio to WWOX and COPG2. Authors note ~25% of clinical AD lack AD pathology at autopsy.
Scope note — postmortem retinal tau pathology ≠ plasma Simoa discrimination in living clinic cases
Limits the claim's scope: a different population, assay, or outcome.
Pathogenic tau can sit in retinal ganglion cells in MCI and AD, with substantial RGC loss.
In 41 donor eyes, MCI-due-to-AD and AD retinas showed pS396-tau and oligomeric tau inside RGCs, hypertrophic somas and death-pathway markers, about 50% RGC loss, and correlations with brain AD pathology, stage, and cognition.
Evidence for the claim as stated.
Clinic plasma+genetics discrimination, biobank GFAP/NfL prognosis, cortical tau PET, and postmortem retinal tau are related Alzheimer’s biology at different compartments, time horizons, and confirmation standards. They do not yield one interchangeable “accuracy number.”
Evidence for the claim as stated.
Open questions
Tensions this paper is part of
From concept pages' “where studies disagree.” Disagreement means the same question; scope means different assays, populations, or outcomes.
Clinic plasma+genetics discrimination, biobank GFAP/NfL prognosis, cortical tau PET, and postmortem retinal tau are related Alzheimer’s biology at different compartments, time horizons, and confirmation standards. They do not yield one interchangeable “accuracy number.”
History
When this study was placed
Dated entries from the concept change log — when this paper was added or removed as support, challenge, or qualifier on a claim.
Placed as a scope qualifier on Alzheimer’s and MCI markers
In Alzheimer’s disease, tau PET burden concentrated in highly connected cortical hubs and higher overall tau associated with weakened cortical connection strength; progressive-supranuclear-palsy patterns differed, showing disease-specific mapping of tau onto networks.
Placed as a scope qualifier on Alzheimer’s and MCI markers
In the AD Cardiff Cohort (1,439 clinical AD cases, 508 older controls), plasma Aβ40/42, P-tau181, NfL, and GFAP plus APOE-ε4 and polygenic risk reached AUC 0.81. Aβ-related peptides were lower in cases; P-tau181, NfL, and GFAP were higher. Case-only GWAS linked the Aβ42/Aβ40 ratio to WWOX and COPG2. Authors note ~25% of clinical AD lack AD pathology at autopsy.
Placed as supporting evidence on Alzheimer’s and MCI markers
In 41 donor eyes, MCI-due-to-AD and AD retinas showed pS396-tau and oligomeric tau inside RGCs, hypertrophic somas and death-pathway markers, about 50% RGC loss, and correlations with brain AD pathology, stage, and cognition.
Placed as supporting evidence on Alzheimer’s and MCI markers
Clinic plasma+genetics discrimination, biobank GFAP/NfL prognosis, cortical tau PET, and postmortem retinal tau are related Alzheimer’s biology at different compartments, time horizons, and confirmation standards. They do not yield one interchangeable “accuracy number.”
Related papers in this topic
Same topic cluster — not a recommendation engine.
- How tau buildup shapes brain networks in dementia
- How does brain structure change in early Parkinson's disease?
- How does brain inflammation affect connectivity and thinking in AD?
- Can a new PET imaging tracer distinguish different tau diseases?
- Does brain region loss predict memory decline in Parkinson's?